Frequently Asked Questions
The market is segmented based on , By Therapy Type (Laser therapy, Behavioral Therapy and Psychiatric Therapy), Route of Administration (Oral, Injectable and Topical), End-Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031.
.
The Global Tuberous Sclerosis Drug Market size was valued at USD 831.20 USD Million in 2023.
The Global Tuberous Sclerosis Drug Market is projected to grow at a CAGR of 7.23% during the forecast period of 2024 to 2031.
The major players operating in the market include Novartis AG (Switzerland), Nobelpharma Co., Ltd. (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Takeda Pharmaceutical Company Limited (Japan), Aucta Pharmaceuticals Inc. (U.K.), Shijiazhuang Yiling Pharmaceutical Co,Ltd. (China), H. Lundbeck A/S (Denmark), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), AstraZeneca (U.K.), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd (Switzerland), Hikma Pharmaceuticals PLC (Jordan), Jazz Pharmaceuticals, Inc. (Ireland), Johnson & Johnson Private Limited (U.S.), and Pfizer Inc. (U.S.).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
